Detailed Information
Cited 1 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
First-Line Nivolumab plus Ipilimumab in Asian Patients With Advanced NSCLC and High TMB (>= 10 mut/Mb): Results From CheckMate 227OA11 First-Line Nivolumab + Ipilimumab in Asian Patients With Advanced NSCLC and High TMB (≥10 mut/Mb): Results From CheckMate 227
- Other Titles
- OA11 First-Line Nivolumab + Ipilimumab in Asian Patients With Advanced NSCLC and High TMB (≥10 mut/Mb): Results From CheckMate 227
- Authors
- Park, K[Park, K.]; Lee, J[Lee, J.]; Sakai, H[Sakai, H.]; Lee, K[Lee, K.]; Ohe, Y[Ohe, Y.]; Kim, S[Kim, S.]; Fukuhara, T[Fukuhara, T.]; Kang, J[Kang, J.]; Yu, C[Yu, C.]; Daga, H[Daga, H.]; Hotta, K[Hotta, K.]; Yokoyama, T[Yokoyama, T.]; Tanaka, H[Tanaka, H.]; Takeda, M[Takeda, M.]; Hellmann, M[Hellmann, M.]; Sheng, J[Sheng, J.]; Nathan, F[Nathan, F.]; Yang, R[Yang, R.]; Nishio, M[Nishio, M.]
- Issue Date
- Dec-2018
- Publisher
- ELSEVIER SCIENCE INC
- Keywords
- Nivolumab; Ipilimumab; Tumor mutational burden; Non-Small Cell Lung Cancer
- Citation
- JOURNAL OF THORACIC ONCOLOGY, v.13, no.12, pp.S1048 - S1048
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF THORACIC ONCOLOGY
- Volume
- 13
- Number
- 12
- Start Page
- S1048
- End Page
- S1048
- ISSN
- 1556-0864
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.